1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sandoz Group Ltd

Sandoz Group Ltd

86.12
EUR
+1.60
(+1.89%)
34.40BMarket Cap
Feb 17Next Earn
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
21.59
23.21
24.14
25.83
- -
Basic EPS, GAAP
1.97
0.18
- -
2.12
- -
Free Cash Flow per Basic Share
1.85
-0.61
0.14
1.88
- -
Dividend per Share
- -
- -
0.5
0.73
- -
Book Value per Share
20.3
20.11
18.95
21.69
20.8
Tangible Book Value per Share
-0.33
-1.18
-1.81
-1.15
-1.81
Basic Weighted Avg Shares
431
430
430
432
434
Sales/Revenue/Turnover
9,306
9,979
10,384
11,157
- -
Operating Margin (%)
13.31
3.76
2.96
12.77
- -
Depreciation Expense
492
525
502
545
- -
Net Income, GAAP
848
77
- -
914
- -
Effective Tax Rate (%)
22.87
38.46
- -
24.28
- -
Profit Margin (%)
9.11
0.77
- -
8.19
- -
Working Capital
-1,938
1,874
1,494
1,270
447
LT Debt
118
4,230
4,666
5,010
4,752
Total Equity
8,760
8,654
8,164
9,385
9,001
Return on Invested Capital (%)
- -
1.98
- -
7.32
- -
Return on Capital (%)
- -
1.78
- -
7.7
- -
Return on Common Equity (%)
- -
0.89
- -
10.42
- -

Capital Structure

USD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
194
673
1,451
LT Borrowings
5,201
4,695
4,465
LT Finance Leases
298
315
287
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
431
433
433
Market Capitalization
23,502
31,622
39,300

Working Capital

USD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
8,374
8,165
8,788
Cash, Cash Equivalents & STI
1,389
1,739
1,250
Accounts Receivable, Net
2,314
2,508
2,565
Inventories
3,077
2,845
2,786
Total Current Liabilities
6,477
6,895
8,341
Payables & Accruals
- -
- -
- -
ST Debt
194
673
1,451
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
14.96%
Free Cash Flow
- -
- -
1,250%
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
7.44%
Total Cash Common Dividend
- -
- -
46.51%

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
10,384
2025
- -
- -
11,157
2026
- -
- -
- -

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
2.12
2026
- -
- -
- -

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.5
2025
- -
- -
0.73
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Richard Saynor
Full Time Employees
23,000
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Centralbahnstrasse 4 Rotkreuz ZG Switzerland 4051
IPO Date
Oct 4, 2023
Website
sandoz.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sandoz Group AG, headquartered in Rotkreuz, Switzerland with operational headquarters in Basel, is the world's leading independent generics and biosimilars pharmaceutical company, spun off from Novartis and incorporated in 2022 following roots dating back to 1886; it develops, manufactures, and markets a broad portfolio of over 1,000 generic products including active ingredients, finished dosage forms of small-molecule drugs, anti-infectives, and intermediates, alongside approximately 30 biosimilars such as protein-based therapies targeting oncology (e.g., recently launched Wyost, Jubbonti, and Pyzchiva), immunology, endocrinology, diabetes, cardiovascular, central nervous system, pain, respiratory, and other therapeutic areas; the company serves healthcare providers and patients in over 100 countries worldwide with high-quality, affordable medicines. Recent strategic developments include signing a definitive agreement in 2025 to acquire Just-Evotec Biologics EU SAS in Toulouse, France for approximately USD 300-350 million plus milestones and royalties to bolster in-house biosimilars manufacturing capabilities via continuous manufacturing technology; investing USD 1.1 billion by 2029 in a new USD 440 million biosimilars production facility in Slovenia to create an end-to-end European hub; strengthening its balance sheet through new bond issuances to repay spin-off term loans and a USD 2 billion revolving credit facility; and advancing a robust pipeline of 28 biosimilars in development targeting a USD 222 billion patent-expiry market opportunity over the next decade.

Company News

Company News APIChatGPT

  • accessnewswire.com

    Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz

  • prnewswire.com

    EirGenix ha firmado el acuerdo de licencia comercial para su segundo biosimilar de HER2, EG1206A

  • prnewswire.com

    EirGenix a signé un accord de licence commerciale pour son deuxième actif biosimilaire HER2, l'EG1206A

  • prnewswire.com

    EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A